Top Health Care Stocks
Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index adding about 0.5% in value while shares of health care companies in the S&P 500 were up almost 0.8% as a group.
In company news, Catalyst Biosciences ( CBIO ) slumped Tuesday after the early-stage biotech company said it expects to begin a pair of clinical trials of the company's next-generation Factor VIIa and Factor IX drug candidates in patients with hemophilia B later this year.
One trial is expected to measure the efficacy trial of its Factor VIIa marzeptacog alfa in patients with hemophilia B with inhibitors in 2017. In the other trial, Catalyst and collaboration partner ISU Abxis are planning to begin a Phase I/II proof-of-concept trial of coagulation Factor IX CB 2679d/ISU304 during the April-to-June period in patients with hemophilia B.
CBIO shares were down 16% at $7.98 apiece, earlier sinking to a session low of $7.59 a share.
In other sector news,
(+) CYNO, Agrees to $1.65 bln buyout offer from Hologic ( HOLX ), which will pay $66 for each CYNO share, a 28.1% premium over Monday's closing price.
(-) AVIR, Vapendavir drug candidate at either 264-mg or 528-mg doses fails to demonstrate a statistically significant reduction in asthma symptomscompared to placebo during Phase IIb clinical trial.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.